Significance of p53 expression in background endometrium in endometrial carcinoma

Virchows Archiv

Volumn 466, Issue 6, 2015, Pages 695-702

  Nguyen, Thuy Thi ^a   Hachisuga, Toru ^a   Urabe, Rie ^a   Kurita, Tomoko ^a   Kagami, Seiji ^a   Kawagoe, Toshinori ^a   Shimajiri, Shohei ^a   Nabeshima, Kazuki ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Estrogen receptor; Immunohistochemistry; Ki 67; Lynch syndrome; p53 signature

Indexed keywords

ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOSARCOMA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MIDDLE AGED; PRECANCER AND CANCER-IN-SITU; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; AGED, 80 AND OVER; BIOSYNTHESIS; CARCINOMA; ENDOMETRIAL NEOPLASMS; HUMANS; LASER CAPTURE MICRODISSECTION; METABOLISM; PATHOLOGY; PRECANCEROUS CONDITIONS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MIDDLE AGED; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84930764197     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1752-5     Document Type: Article

References (22)

1. Vogelstein B, Lane D, Levine A (2000) Surfing the p53 network. Nature 408:307–310
2. Nenutil R, Smardova J, Pavlova S et al (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259
3. Maia H, Maltez A, Studart E et al (2004) Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle. BJOG 111:1242–1247
4. Folkins AK, Jarboe EA, Saleemuddin A et al (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with heterozygous BRCA mutations. Gynecol Oncol 109:168–173
5. Crum CP, McKeon FD, Xian W (2012) BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 22:S29–S34
6. Ellenson LH, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ (2011) Serous carcinoma. In: Kurman RJ, Ellenson LH, Ronnett BM (eds) Blaustein’s pathology of the female genital tract, 6th edn. Springer, New York, pp 394–452
7. Zheng W, Xiang L, Fadare O, Kong B (2011) A proposed model for endometrial serous carcinogenesis. Am J Surg Pathol 35:e1–e14
8. Jarboe EA, Pizer E, Miron A, Monte N, Mutter GL, Crum CP (2009) Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 22:345–350
9. Zhang X, Liang SX, Jia L et al (2009) Molecular identification of “latent precancers” for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol 174:2000–2006
10. Koi C, Hachisuga T, Murakami M et al (2015) Overexpression of p53 in the endometrial gland in postmenopausal women. Menopause 22:104–107
11. Mutter GL, Monte NM, Neuberg D, Ferenczy A, Eng C (2014) Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res 74:2796–2802
12. Schlosshauer PW, Ellenson LH, Soslow RA (2002) β-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 15:1032–1037
13. Zhang L, Liu Y, Hao S, Woda BA, Lu D (2011) IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas. Am J Surg Pathol 35:868–872
14. Yemelyanova A, Ji H, Shih IM, Wang TL, Wu LSF, Ronnett BM (2009) Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas. Immunohistochemical analysis of 201 cases. Am J Surg Pathol 33:1504–1514
15. Han CP, Kok LF, Wang PH et al (2009) Scoring of p16INK4a immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. Mod Pathol 22:797–806
16. Lu KH, Daniels M (2013) Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Familial Cancer 12:273–277
17. Seifert M, Reichrath J (2006) The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J Mol Hist 37:301–307
18. Steinke V, Holzapfel S, Loeffler M et al (2014) Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. Int J Cancer 135:69–77
19. Zorn K, Bonome T, Gangi L et al (2005) Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 11:6422–6430
20. Kuhn E, Wu RC, Guan B et al (2012) Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. JNCI 204:1503–1513
21. Comin CE, Saleva C, Messerini L (2007) h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 31:1139–1148
22. Matsuo K, Sheridan TB, Mabuchi S et al (2014) Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol 133:473–479